Mitumomab
From Wikipedia, the free encyclopedia
|
Mitumomab
|
|
|
|
|
| Source | Mouse |
| Target | CD3 ganglioside |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mitumomab is a mouse, anti-Idiotypic monoclonal antibody that targets GD3 ganglioside, which is over-expressed predominantly on tumours origination from the neuroectoderm.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Abagovomab, Afelimomab, Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Besilesomab, Biciromab brallobarbital, Capromab, Detumomab, Dorlimomab aritox, Edobacomab, Edrecolomab, Elsilimomab, Enlimomab, Enlimomab pegol, Epitumomab, Epitumomab cituxetan, Fanolesomab, Faralimomab, Gavilimomab, Ibritumomab tiuxetan, Igovomab, Imciromab, Inolimomab, Lemalesomab, Maslimomab, Minretumomab, Mitumomab, Nacolomab tafenatox, Nerelimomab, Nofetumomab merpentan, Odulimomab, Oregovomab, Pemtumomab, Pintumomab, Satumomab, Sulesomab, Taplitumomab paptox, Telimomab aritox, Tositumomab, Vepalimomab, Zolimomab aritox
